Study #2024-1369
Monitoring, detoxifying, and rebalancing metals during acute myeloid leukemia (AML) therapy, a phase 2 randomized study
MD Anderson Study Status
Enrolling
Treatment Agent
DMSA, Ca-EDTA, Magnesium Sulfate, Multivitamin
Description
The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia (AML)
Study phase:
Phase II
Physician name:
Maro Ohanian
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.